Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.

Cystic fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Monday saw the release of JMP Securities' latest industry overview for the biotechnology sector, which highlighted key events from January 2025. The report noted a modest resurgence in the sector, ...

Digital health firms in the city raised $4 billion in 2024, up 60% from the previous year, according to a report released ...

Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Other stories cover U.S. health agencies' website changes, Metsera's IPO, Gaza's ongoing food crisis, the U.S. exit from WHO, and AbbVie's profit predictions. This image is AI-generated and does not ...

Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...

GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...